How BCL2 protein changes affect HIV infection and treatment response
Official title: IMPACT OF BCL2 PHOSPHORYLATION ON HIV DYNAMICS, RESERVOIR SIZE AND SUSCEPTIBILITY TO VENETOCLAX
Funded at Mayo Clinic Rochester · NIH-11118296 · Data updated 2026-11-12
This study is looking at how a protein called BCL2 changes during HIV infection and how that affects the way a drug called Venetoclax works, with the goal of finding better ways to treat people living with HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $682,446 |
| NIH project number | 1R56AI183801-01 |
| Project ID | NIH-11118296 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who have not achieved viral suppression or have a high viral load.
✕Less likely to help
Patients who are not infected with HIV or those who have achieved long-term viral suppression may not benefit from this research.
What this research studies
This research investigates the role of BCL2 protein phosphorylation in the dynamics of HIV infection and how it influences the effectiveness of the drug Venetoclax. By examining T cells that persist after HIV infection, the study aims to understand how modifications to BCL2 can affect cell death and the size of the HIV reservoir in the body. The researchers will utilize advanced techniques, including CRISPR technology, to create specific cell lines that will help them analyze the interactions between BCL2, HIV replication, and treatment responses. This work could lead to improved strategies for targeting HIV-infected cells and enhancing treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HIV by enhancing the ability to eliminate infected cells.
How similar studies have gone: Previous research has shown promising results with Venetoclax in targeting HIV-infected cells, indicating that this approach has potential for success.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Badley, Andrew D — Mayo Clinic Rochester
- Study coordinator: Badley, Andrew D
Related research
Other NIH-funded projects on the same topics.
-
All of Us Biobank expansion and biospecimen program
A large Mayo Clinic–led project to collect and store biological samples from a diverse group of adults in the U.S. to advance precision medicine.
-
How baclofen and spinal cord stimulation interact in people with spinal cord injury
This study looks at how a common antispasmodic medicine (baclofen) works together with spinal cord stimulation in people who have spinal cord injuries and live with spasticity.
-
Pragmatic midodrine trial to reduce ICU vasopressor use in septic shock
A practical, patient-focused trial tests whether taking oral midodrine can lessen the need for IV vasopressors and shorten ICU stays for people with sepsis-related low blood pressure.
-
Estrogen’s role in eye pressure and glaucoma risk
A Mayo Clinic team is studying how estrogen and its receptors might control eye pressure in people with a common form of glaucoma.
-
Gut-brain connections in Parkinson’s disease: how the gut and environment shape symptoms
A Mayo Clinic team is studying how gut problems, environmental factors, and genetics together influence Parkinson’s disease and its GI symptoms to find biomarkers and better understanding of the disease.
-
ARTFL LEFFTDS Frontotemporal Dementia study cycle 2
This NIH grant supports a longitudinal study to understand and track frontotemporal lobar degeneration (FTLD) and related disorders in people, aiming to uncover biomarkers and disease progression information that could help patients and families.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.